ArticleAmerican journal of translational research2025
Clinical efficacy of osmotic release oral system methylphenidate combined with electroencephalographic biofeedback and sensory integration training in children with attention deficit hyperactivity disorder.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy of osmotic release oral system methylphenidate (OROS-MPH) combined with electroencephalographic (EEG) biofeedback and sensory integration training in children with attention deficit hyperactivity disorder (ADHD).
methodsThis retrospective study included 98 children diagnosed with ADHD who were treated at Longquanyi District of Chengdu Maternity & Child Health Care Hospital between January 2023 and January 2025. Based on treatment modality, 53 patients received OROS-MPH alone (control group), while 45 received additional EEG biofeedback and sensory integration training (observation group). The intervention period was 12 weeks. Clinical outcomes were assessed using the Swanson, Nolan, and Pelham IV Scale (SNAP-IV), Conners' Parent Rating Scale (CPRS-48), and the China-Wechsler Intelligence Scale for Children (C-WISC). Physiological indices included EEG wave frequencies (θ, β, SMR), cerebral blood flow velocities, and plasma levels of adrenocorticotropic hormone (ACTH), cortisol, norepinephrine (NE), and dopamine (DA). Adverse events were recorded.
resultsAfter intervention, the observation group showed significantly greater reductions in SNAP-IV and CPRS-48 scores, and greater increases in all C-WISC indices compared with the control group (
conclusionMultimodal therapy combining OROS-MPH with EEG biofeedback and sensory integration training demonstrates superior efficacy over medication alone in improving behavioral symptoms, cognitive function, and neurophysiological parameters in children with ADHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.